BioCryst delivered strong Q3 2025 results with robust ORLADEYO sales pushing revenue to $159.4M and swinging to a net income of $12.9M from a loss last year. The company repaid its Pharmakon term debt and raised full-year guidance.

BioCryst Pharmaceuticals delivered its best financial performance in company history during the second quarter of 2025, primarily due to better-than-expected revenue growth from ORLADEYO and substantial operating profit. The company also strengthened its financial position through an additional debt paydown and plans to retire all remaining term debt with proceeds from the sale of its European ORLADEYO business.

BioCryst delivered strong Q1 2025 results with $145.5 million in revenue driven by significant growth in ORLADEYO sales, leading to a return to profitability and improved full-year guidance.

BioCryst Pharmaceuticals posted total revenue of $131.5 million in Q4 2024, a 40.8% increase year-over-year. ORLADEYO sales grew 36.6% to $124.2 million. The company's GAAP net loss improved to $26.8 million from $61.7 million in the prior year quarter. Non-GAAP operating profit reached $16.8 million, compared to a loss of $26.2 million in Q4 2023.

BioCryst Pharmaceuticals reported a successful third quarter in 2024, marked by a 35.1% increase in total revenues to $117.1 million. The company saw significant growth in ORLADEYO net revenue, reaching $116.3 million, and achieved GAAP operating profit of $7.7 million. The company has adjusted its full-year 2024 ORLADEYO revenue guidance to $430-$435 million and introduced total product revenue guidance of $443-$448 million.

BioCryst announced a successful second quarter in 2024, marked by a 34% increase in ORLADEYO net revenue to $108.3 million and a revised full-year revenue guidance of $420-$435 million. The company reported a GAAP operating profit of $8.8 million and a non-GAAP operating profit of $21.9 million. They are also advancing their pipeline programs and moving closer to profitability.

BioCryst's Q1 2024 total revenues reached $92.8 million, driven by ORLADEYO net revenue of $88.9 million, a 30% increase year-over-year. The company is increasing its revenue guidance for 2024.

BioCryst reported Q4 2023 total revenues of $93.4 million, driven by ORLADEYO net revenue of $90.9 million. The company's net loss for the quarter was $61.7 million, or $0.31 per share. They anticipate operating profit in 2024 and approaching positive EPS and cash flow in the second half of 2025.

BioCryst's Q3 2023 revenues reached $86.7 million, driven by ORLADEYO's growth, while R&D expenses decreased and SG&A expenses increased. The company anticipates achieving at least $320 million in ORLADEYO revenue for the full year 2023.

BioCryst's second quarter results show a strong performance with total revenues of $82.5 million, driven by $81.0 million in ORLADEYO net revenue, marking a 24% increase year-over-year. The company is on track to achieve its full-year ORLADEYO revenue target of at least $320 million.

BioCryst's Q1 2023 earnings report showed strong growth in ORLADEYO net revenue, increasing 38% year-over-year to $68.4 million. The company's new patient growth also saw a significant rise, with a 46% increase in patients on therapy year-over-year. BioCryst anticipates ORLADEYO net revenue to be no less than $320 million for the full year 2023.

BioCryst Pharmaceuticals reported a strong Q4 2022, with total revenues of $79.5 million, driven by ORLADEYO net revenue of $70.7 million. The company's net loss was $71.5 million, or $0.38 per share. They anticipate ORLADEYO net revenue to be no less than $320 million in 2023.

BioCryst Pharmaceuticals reported strong Q3 2022 financial results, driven by ORLADEYO's net revenue of $66.0 million. Total revenues increased to $75.8 million, and the company is on track to more than double ORLADEYO sales in 2022 compared to 2021.

BioCryst reported total revenues of $65.5 million, driven by $65.2 million in ORLADEYO net revenue. The company's net loss was $58.9 million, or $0.32 per share. Cash, cash equivalents, restricted cash and investments totaled $418.9 million at June 30, 2022.

BioCryst Pharmaceuticals reported total revenues of $49.9 million for the first quarter of 2022, primarily driven by $49.7 million in ORLADEYO net revenue. The company is investigating BCX9930 and plans to discuss a revised dosing protocol with regulators by the end of the third quarter.

BioCryst's Q4 2021 saw a significant increase in total revenue, driven by ORLADEYO sales. The company is focused on growing ORLADEYO revenue and advancing its complement program.

BioCryst announced Q3 2021 financial results, with total revenues of $41.0 million, primarily driven by $37.0 million in ORLADEYO net revenue. The company expects full-year 2021 ORLADEYO net revenue to be between $115 million and $120 million.

BioCryst announced its Q2 2021 financial results, highlighted by total revenues of $50.0 million, driven by ORLADEYO net revenue of $28.5 million and a $15 million milestone payment from Torii Pharmaceutical. The company's net loss for the quarter was $43.2 million, or $0.24 per share.

BioCryst's Q1 2021 total revenues were $19.1 million, primarily driven by $10.9 million in ORLADEYO net revenue. The company's net loss was $64.3 million, or $0.36 per share. Cash, cash equivalents, restricted cash and investments totaled $244.4 million at March 31, 2021.

BioCryst Pharmaceuticals reported Q4 2020 financial results, featuring a revenue of $4.0 million, a net loss of $60.5 million, and increased R&D and SG&A expenses. The company highlighted the approvals of ORLADEYO in the U.S. and Japan, advancements in the BCX9930 program, and a strong cash position of $302.6 million.

BioCryst announced its third quarter financial results, with total revenues of $6.1 million compared to $1.8 million in the third quarter of 2019. The net loss for the quarter was $46.1 million, or $0.26 per share. The company's cash, cash equivalents, restricted cash and investments totaled $148.5 million at September 30, 2020.

BioCryst announced Q2 2020 financial results, with total revenues of $2.9 million compared to $1.4 million in Q2 2019. Net loss for the quarter was $38.6 million, or $0.24 per share. The company's cash, cash equivalents, and investments totaled $191.6 million at the end of the quarter.

BioCryst reported a decrease in total revenues to $4.8 million compared to $5.9 million in the first quarter of 2019. The net loss for the quarter was $37.6 million, or $0.24 per share, compared to a net loss of $31.1 million, or $0.28 per share, for the first quarter of 2019. The company's cash, cash equivalents, and investments totaled $114.6 million at the end of March 2020.

BioCryst's Q4 2019 total revenues increased significantly to $39.7 million compared to $2.7 million in Q4 2018, primarily due to the recognition of revenue from the Torii commercialization rights agreement and RAPIVAB product sales. The net loss for the quarter was $2.6 million, a substantial improvement from the $27.4 million loss in the same period of the previous year.